Clinical usefulness of positron emission tomography in the assessment of myocardial viability;Utilidad clínica de la tomografía de emisión de positrones (PET) en la valoración de la viabilidad miocárdica

Revista Espanola de Cardiologia

Volumn 50, Issue 9, 1997, Pages 605-611

  Coma Canella, Isabel ^a   García Velloso, María José ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Positron emission tomography (PET); Viability

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; OXYGEN; RADIOPHARMACEUTICAL AGENT; THALLIUM; WATER;

COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORONARY ARTERY DISEASE; HEART CONTRACTION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART MUSCLE REVASCULARIZATION; HUMAN; METABOLISM; METHODOLOGY; OXYGEN CONSUMPTION; REVIEW; SCINTISCANNING;

CORONARY DISEASE; FLUORODEOXYGLUCOSE F18; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; MYOCARDIUM; OXYGEN CONSUMPTION; OXYGEN RADIOISOTOPES; RADIOPHARMACEUTICALS; THALLIUM RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED; VENTRICULAR DYSFUNCTION, LEFT; WATER;

EID: 0031230116     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(97)73272-x     Document Type: Review

References (44)

1. Martí JM. Tomógrafo de emisores de positrones. En: Richter JA, Martí JM, editores. PET. Tomografía molecular. Fundamentos y aplicaciones. Madrid: Ediciones Eseuve, 1993; 17-40.
2. De Silva R, Camici PG. Role of positron emission tomography in the investigation of human coronary circulatory function. Cardiovasc Res 1994; 28: 1.595-1.612.
3. Marinho NVS, Keogh BE, Costa DC, Lammerstma AA, Ell PJ, Camici PG. Pathophysiology of chronic left ventricular dysfunction. New insights from the measurement of absolute myocardial blood flow and glucose utilization. Circulation 1996; 93: 737-744.
4. Ratlib O, Phelps ME, Huang S, Henze E, Selin CE, Schelbert HR. Positron tomography with deoxyglucose for estimating local myocardial glucose metabolism. J Nucl Med 1982; 23: 577-586.
5. Gallagher BM, Ansari A, Atkins H. Radiopharmaceuticals. XXVII: 18F-labeled 2-deoxy-2-fluoro-D-glucose as a radiophamaceutical for measuring regional myocardial glucose metabolism in vivo: tissue distribution and imaging studies in animals. J Nucl Med 1977; 18: 990-996.
6. Marshall RC, Tillisch JH, Phelps ME, Huang SC, Carson R, Henze E et al. Identification and differentiation of resting myocardial ischemia and infarction in man with positron computed tomography, 18F-labeled fluorodeoxyglucose and N-13 amonia. Circulation 1981; 64: 766-778.
7. Tamaki N, Yonekura Y, Yamashita K, Saji H, Magata Y, Senda M et al. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 1989; 64: 860-865.
8. Opie LH. Effects of regional ischemia on metabolism of glucose and fatty acids: relative rates of aerobic and anaerobic energy production during myocardial infarction and comparison with effects of anoxia. Circ Res 1976; 38 (Supl 1): 52-74.
9. Camici P, Ferrannini E, Opie LH. Myocardial metabolism in ischemic heart disease: basic principles and application to imaging by positron emission tomography. Prog Cardiovasc Dis 1989; 32: 217-238.
10. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 273: E214-E223.
11. Ohtake T, Yokoyama I, Watanabe T, Momose T, Serezawa T, Nishikawa J et al. Myocardial glucose metabolism in noninsulindependent diabetes mellitus patients evaluated by FDG-PET. J Nucl Med 1995; 36: 456-463.
12. DiCarli MF, Asgarzadie F, Schelbert HR, Brunken RC, Laks H, Phelps ME et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ishemic cardiomyopathy. Circulation 1995; 92: 3.436-3.444.
13. Yoshida K, Gould KL. Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3 year mortality with and without revascularization. J Am Coll Cardiol 1993; 22: 984-997.
14. Tillisch JH, Brunken R, Marshall R, Schwaiger M, Mandelkorn M, Phelps M et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314: 884-888.
15. Gropler RJ, Geltman EM, Sampathkumaran KS, Pérez JE, Moerlein SM, Sobel BE et al. Functional recovery after revascularization for chronic coronary artery disease is dependent on maintenance of oxidative metabolism. J Am Coll Cardiol 1992; 20: 569-577.
16. Lucignani G, Paolini G, Landoni C, Zuccari M, Paganelli G, Galli L et al. Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deosy-D-glucose positron emission tomography in patients with coronary artery disease. Eur J Nucl Med 1992; 19: 874-881.
17. Carrel T, Jenni R, Haubold-Reuter S, Von Schulthess G, Pasic M, Turina M. Improvement in severely reduced left ventricular function after surgical revascularization in patients with preoperative myocardial infarction. Eur J Cardiothorac Surg 1992; 6: 874-881.
18. Neinaber CA, Brunken RC, Sherman CT, Yeatman LA, Gambhir SS, Krivokapitch J et al. Metabolic and functional recovery of ischemic human myocardium after coronary angioplasty. J Am Coll Cardiol 1991; 18: 966-978.
19. DiCarli M, Khanna S, Davidson M, Harris G, Brunken R, Czernin J et al. The value of PET for predicting improvement in heart failure symptoms in patients with coronary artery disease and severe left ventricular dysfunction [resumen]. J Am Coll Cardiol 1993; 21 (Supl): 129A.
20. Camici P, Ferrannini E, Opie LH. Myocardial metabolism in ischemic heart disease: basic principles and application to imaging by positron emission tomography. Progr Cardiovasc Dis 1989; 32: 217-238.
21. Dnuuti MJ, Saraste M, Nuutila P, Harkonen R, Wegelius U, Haapanen A et al. Myocardial viability: fluorine-18-deoxyglucose positron emission tomography in prediction of wall motion recovery after revascularization. Am Heart J 1994; 127: 785-796.
22. Tamaki N, Kawamoto M, Tadamura E, Magata Y, Yonekura Y, Nohara R et al. Prediction of reversible ischemia after revascularization. Perfusion and metabolic studies with positron emission tomography. Circulation 1995; 91: 1.697-1.705.
23. Baer FM, Voth E, Schneider CA, Theissen P, Schicha H, Sechtem U. Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with (18F) fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability. Circulation 1995; 91: 1.006-1.015.
24. Tamaki N, Yonekura Y, Yamashita K, Senda M, Saji H, Hashimoto T et al. Relation of left ventricular perfusion and wall motion with metabolic activity in persistent defects on thallium-201 tomography in healed myocardial infarction. Am J Cardiol 1988; 62: 202-208.
25. Brunken RC, Kottou S, Nienaber CA, Schwaiger M, Ratib OM, Phelps ME et al. PET detection of viable tissue in myocardial segments with persistent defects at TI-201 SPECT. Radiology 1989; 65: 65-73.
26. Tamaki N, Yonekura Y, Yamashita K, Mukai T, Magata Y, Hashimoto T et al. SPECT thailium-201 tomography and positron tomography using N-13 ammonia and F-18 fluorodeoxyglucose in coronary artery disease. Am J Cardiac Imaging 1989; 3: 3-9.
27. Kiat H, Berman DS, Maddahi J, Yang LD, Van Train K, Rozanski A et al. Late reversibility of tomographic myocardial thallium-201 defects: an accurate marker of myocardial viability. J Am Coll Cardiol 1988; 12: 1.456-1.463.
28. Gutman J, Berman DS, Freeman M, Rozanski A, Maddahi J, Waxman A et al. Time to completed redistribution of thallium-201 in exercise myocardial scintigraphy: relationship to the degree of coronary artery stenosis. Am Heart J 1983; 106: 989-995.
29. Brunken RC, Mody FV, Hawkins RA, Neinaber C, Phelps ME, Schelbert HR. Positron emission tomography detects metabolic activity in myocardium with persistent 24-hour single photon emission computed tomography 201-Tl defects. Circulation 1992; 86: 1.357-1.369.
30. Burt RW, Perkins OW, Oppenheim-BE, Schauwecker DS, Stein L, Wellman HN et al. Direct comparison of fluorine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPECT for detection of myocardial viability. J Nucl Med 1995; 36: 176-179.
31. Iida H, Rhodes CG, De Silva R, Yamamoto Y, Jones T, Araujo LI. Myocardial tissue fraction. Correction for partial volume effects and measure of tissue viability. J Nucl Med 1991; 32: 2.169-2.175.
32. Yamamoto Y, De Silva R, Rhodes CG, Araujo LI, Iida H, Rechavia E et al. A new strategy for the assessment of viable myocardium and regional myocardial blood flow using 15O-water and dynamic positron emission tomography. Circulation 1992; 86: 167-178.
33. Camici PG, Gropler RJ, Jones T, L'Abbate A, Maseri A, Melin JA et al. The impact of myocardial blood flow quantitation with PET on the understanding of cardiac diseases. Eur Heart J 1996; 17: 25-34.
34. Uren NG, Melin JA, De Bruyne B, Wijns W, Baudhuin T, Camici PG. Myocardial blood flow as a function of coronary stenosis severity in man. N Engl J Med 1994; 330: 1.782-1.788.
35. De Silva R, Yamamoto Y, Rhodes GC, Iida H, Nihoyannopoulos P, Davies G et al. Preoperative prediction of the outcome of coronary revascularization using positron emission tomography. Circulation 1992; 86: 1.738-1.742.
36. Tillisch J, Brunken R, Schwaiger M, Mandelkern M, Phelps M, Schelbert HR. Reversal of cardiac wall motion abnormalities predicted by using positron emission tomography. N Engl J Med 1985; 314: 884-888.
37. Schwaiger M, Brunken R, Grover-McKay M, Krivokapich J, Child J, Tillisch J et al. Regional myocardial metabolism in patients with acute myocardial infarction assessed by positron emission tomography. J Am Coll Cardiol 1986; 8: 800-808.
38. Knuuti MJ, Nuutila P, Ruotsalainen U, Teras M, Saraste M, Harkonen R et al. The value of quantitative analysis of glucose utilization in detection of myocardial viability by PET. J Nucl Med 1993; 34: 2.068-2.075.
39. Stahl LD, Averesano TR, Becker LC. Selective enhancement of function of stunned myocardium by increased flow. Circulation 1986; 74: 843-851.
40. Gropler RJ. 11C-acetate in the study of ischemic heart disease. En: Schwaiger M, editor. Cardiac Positron Emission Tomography. Boston: Kiuwer Academic Publ., 1996; 227-240.
41. Vanoverschelde JL, Wijns W, Depré C, Essamri B, Heyndrickx GR, Borgers M et al. Mechanisms of chronic regional postischemic dysfunction in humans. New insights from the study of noninfarcted collateral-dependent myocardium. Circulation 1993; 87: 1.513-1.523.
42. Conversano A, Herrero P, Geltman EM, Pérez JE, Bergmann SR, Gropler RJ. Differentiation of stunned from hibernating myocardium by positron emission tomography. Circulation 1992; 86 (Supl 1): 427.
43. Chapman JD, Franco AJ, Sharplin J. A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer 1981; 43: 546-550.
44. Martin GV, Grierson JR, Caldwell JH. Imaging hypoxic myocardium. En: Schwaiger M, editor. Boston: Kluwer Academic Publishers, 1996; 279-293.